secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2026-06-22T11:45:06+00:00
Accession:  0001140361-26-025844
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 5.07, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie to acquire Apogee Therapeutics for $135.11/share, ~$10.9B equity value
-----------------------------------------------------------------------------

- AbbVie to acquire all outstanding shares of Apogee for $135.11 per share in cash, total equity value ~$10.9 billion.
- Acquisition expected to close in Q3 2026, subject to Apogee shareholder approval and regulatory clearances.
- Apogee's lead asset zumilokibart (APG777) targets IL-13 for atopic dermatitis; APG273 targets IL-13/TSLP for asthma.
- Voting agreement with certain stockholders to support merger; termination fee of $381.3M payable under specified conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000114036126025844/0001140361-26-025844-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000114036126025844/ef20076505_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-025844

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer